Related Experiment Video

Updated: Jun 13, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors

Robert Y C Yang1, Katherine S Yang, Linda J Pike

  • 1Department of Biochemistry and Molecular Biophysics, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.

Chemical Biology & Drug Design
|May 12, 2010
PubMed

Insights

A novel small molecule, NSC56452, inhibits epidermal growth factor (EGF) receptor dimerization and activation. This compound offers a new therapeutic strategy for aggressive cancers driven by EGF receptor overexpression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Epidermal growth factor (EGF) receptor overexpression is linked to aggressive cancers, including breast carcinoma and glioblastoma.
  • EGF receptor signaling drives tumor initiation, progression, and metastasis.
  • Inhibiting EGF receptor dimerization is a potential therapeutic strategy.

Purpose of the Study:

  • To identify and characterize small-molecule inhibitors of EGF receptor dimerization.
  • To evaluate the efficacy of a novel compound, NSC56452, in blocking EGF receptor activation.

Main Methods:

  • Virtual screening to identify potential inhibitors.
  • Experimental validation of NSC56452's activity.
  • Chemical cross-linking and luciferase fragment complementation assays to measure dimer formation.
  • Cell growth inhibition assays using HeLa cells.

Main Results:

  • NSC56452 was identified as an inhibitor of EGF receptor kinase activation.
  • The compound dose-dependently blocked EGF-stimulated homodimer formation.
  • NSC56452 inhibited the growth of HeLa cells.
  • This represents a novel mechanism of action, targeting dimerization rather than the kinase domain.

Conclusions:

  • NSC56452 is a first-generation, drug-like small molecule that inhibits EGF receptor activation by blocking dimerization.
  • This compound provides a new avenue for developing targeted therapies against cancers with EGF receptor overexpression.
  • Targeting protein-protein interactions, like EGF receptor dimerization, is a viable therapeutic approach.

More Related Videos

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy09:16

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...